Payden & Rygel
- SEC CIK
- 0000919219
- Latest filing
- Jul 31, 2026
BMY holding history
Bristol Myers Squibb Co in every 13F filed by Payden & Rygel, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
BMY overviewAll 13F holders of BMYFull Q2 2026 holdings
- Shares (Q2 2025)
- 0
- Sold out in Q2 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 15
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2025 | 0 | $0 | 0.0% | −292,800−100.0% | Sold out | Holders |
| Q1 2025 | 292,800 | $17.9M | 1.5% | +45,000+18.2% | Added | Holders |
| Q4 2024 | 247,800 | $14.0M | 1.2% | +247,800 | New | Holders |
| Q2 2024 | 0 | $0 | 0.0% | −3,800−100.0% | Sold out | Holders |
| Q1 2024 | 3,800 | $206.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2023 | 3,800 | $195.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2023 | 3,800 | $221.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2023 | 3,800 | $243.0K | <0.1% | −203,940−98.2% | Reduced | Holders |
| Q1 2023 | 207,740 | $14.4M | 0.9% | −235,320−53.1% | Reduced | Holders |
| Q4 2022 | 443,060 | $31.9M | 1.7% | −4,200−0.9% | Reduced | Holders |
| Q3 2022 | 447,260 | $31.8M | 1.9% | +77,800+21.1% | Added | Holders |
| Q2 2022 | 369,460 | $28.4M | 1.7% | 00.0% | Unchanged | Holders |
| Q1 2022 | 369,460 | $27.0M | 1.4% | −352,500−48.8% | Reduced | Holders |
| Q4 2021 | 721,960 | $45.0M | 2.1% | +5,800+0.8% | Added | Holders |
| Q3 2021 | 716,160 | $42.4M | 2.2% | +371,460+107.8% | Added | Holders |
| Q2 2021 | 344,700 | $23.0M | 1.1% | −123,600−26.4% | Reduced | Holders |
| Q1 2021 | 468,300 | $29.6M | 1.4% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.